Clinical Trial Detail

NCT ID NCT03597282
Title A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced Melanoma
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Neon Therapeutics, Inc.
Indications

melanoma

Therapies

Ipilimumab + Nivolumab

APX005M + Nivolumab

Ipilimumab + NEO-PV-01 + Nivolumab + Poly ICLC

APX005M + NEO-PV-01 + Nivolumab + Poly ICLC

Nivolumab + Poly ICLC

NEO-PV-01 + Nivolumab + Poly ICLC

Age Groups: senior adult

No variant requirements are available.